Huawei Cloud: Thrive with the Cloud and Reshape Industries with AI

SHANGHAI, Sept. 20, 2024 /PRNewswire/ -- At HUAWEI CONNECT 2024, Executive Director of the Board of Huawei and CEO of Huawei Cloud Zhang Ping'an delivered a keynote speech "Thrive with the Cloud: Reshaping Industries with AI". Zhang states that enterprises must seize opportunities in the intelligent era and use AI to build competitive advantages. The key is to adopt an AI-native mindset now.

First, enterprises should actively embrace AI, open up industry scenarios, and develop enterprise AI platforms. This will enable AI to serve their core business. Today, Huawei Cloud Pangu Models have been applied in more than 30 industries and 400 scenarios.

Second, AI computing power is critical. Enterprises need to build AI-native cloud infrastructure that matches their requirements. Zhang officially released CloudMatrix to interconnect and pool all resources including CPUs, NPUs, DPUs and memory. It marks an evolution from monolithic to matrix compute. CloudMatrix comprises an AI-native cloud infrastructure in which everything can be pooled, peer-to-peer, and composed, providing enterprises with abundant AI computing power.

Third, data quality determines the effectiveness of AI models. We need to build knowledge-centric data foundations to enable data to serve AI better. Huawei Cloud has fully upgraded DataArts to provide customers with AI-oriented and knowledge-centric data foundations. The updated features include AI+data convergence engines, data development and governance, knowledge services, and AI+data application enablement services.

Fourth, build suitable AI models based on business applications. We must abandon the misconception that larger models are better. It is not feasible to address all needs with just one foundation model. Pangu Models 5.0 are available in different sizes, with parameters in the billions, tens of billions, hundreds of billions, and trillions. The complete series of Pangu models meet practically all business application needs.

In addition, Huawei Cloud's Pangu 5.0 models enhance spatiotemporal controllable generation (STCG) in the field of multimodal generation. For autonomous driving，the Pangu model can generate driving scenarios that accurately mirror the physical world. It can generate videos that reflect normal driving scenarios, random road conditions and accidental and aggressive driving, allowing automotive enterprises to train autonomous driving more efficiently.

Huawei Cloud officially released the Mainframe-to-Cloud Solution, designed to help customers develop new core systems on the cloud with high availability, easy O&M, and better agility, helping customers achieve 99.999% financial-grade high availability. Currently, most banks in China have chosen Huawei to build their new core systems on the cloud.

Tao Jingwen, Huawei's Director of the Board and President of the Quality, Business Process & IT Mgmt Dept, recounted Huawei's digital transformation journey. Huawei has developed a methodology, which can be broken down into three layers, five phases, and eight steps. The three layers are redefining intelligent business, AI model development and delivery, and ongoing optimization of intelligent applications. The five phases are identifying suitable scenarios, reshaping processes, transforming organizations, optimizing corporate data, and adopting AI applications.

Bruno Zhang, CTO of Huawei Cloud, presented insights on how Huawei Cloud is leveraging AI to reshape data centers, infrastructure, and cloud services. He also addressed the construction of an AI-native cloud designed to accelerate intelligence in industries. The "1+N" Pangu assistant system, unveiled by Mr. Zhang, signifies a new era in cloud service interaction. The system includes Pangu Doer, and the myriad use cases in product R&D, data analytics, security, and office collaboration, where Pangu models are trained using the scenario-specific data, know-how, and practices to enhance cloud services and boost efficiency with tailored AI.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Huawei Cloud: Thrive with the Cloud and Reshape Industries with AI

Huawei Cloud: Thrive with the Cloud and Reshape Industries with AI

BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place from September 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and researchers from around the globe, showcasing the latest advancements in the field and providing high-quality educational and networking opportunities for oncology professionals.

Biosyngen, an innovative biotechnology company specializing in immune cell therapies, has showcased its groundbreaking technology on gene-modified, functionally enhanced tumor-infiltrating lymphocytes (TILs) derived from liver cancer biopsy samples.

BioSyngen has secured ten clinical trial approvals in China and the U.S. for its innovative fourth-generation oncology therapies. Currently, our leading pipeline product, BRG01, is in the pivotal Phase II clinical trial stage for solid tumors. Additionally, the first patients have been enrolled in the Phase I trials for our other groundbreaking therapies, BST02 and BRL03, with completion of Phase I trials anticipated later this year.

Abstract Title

Pre-clinical Development of Genetically Modified Tumor-infiltrating Lymphocytes using Biopsy Samples from Liver Cancer Patients

Abstract No.

1034P

Tumor-infiltrating lymphocytes (TILs) are heterogeneous lymphocyte populations within the tumor microenvironment that contains T cells capable of recognizing tumor- or virus-associated antigens. In February of this year, the FDA approved the first TIL-based therapy used with IL-2 for advanced metastatic/recurrent melanoma. However, due to the variability in T cell infiltration between hot and cold tumors, differential abundance of antigen-specific T cells with robust immune response functionality, and the dependence of TIL anti-tumor efficacy on concomitant use of high-dose IL-2 combination therapy, the therapeutic applications of non-edited TILs are quite limited outside of melanoma.

To address these challenges, Biosyngen has developed a proprietary platform for expanding TILs from biopsy samples, achieving production of 10¹¹ cells within four weeks. Additionally, the company has established a stable gene modification platform that reprograms TIL metabolism, enhances TIL activity and sustained antitumor efficacy by expressing membrane anchor proteins. Anti-tumor efficacy has significantly enhanced (without IL-2 co-injection) and no obvious toxicity observed.

Biosyngen houses best-in-class proprietary TIL platform aiming to expand the clinical applications of TIL technology with following features:

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting

Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting